Cialis gaining on Viagra
Eli Lilly and Co. figured out how advertises its erectile-dysfunction medicine in Italy and the solution seemed natural: hold a series of tango workshops to help couples revive their passions.
Just like a pro couple who danced on stage, Lilly and its partners in medical market, give their costumers possibility to talk and find an answer about their sexual health problems by providing them access to counselors and medical experts.
Cialis situation at the European market is very important for Lilly, after it gets approval to sell its one-a-day version of the erectile-dysfunction medicine there. Lilly also targets U.S. to get approval there later this year.
Only Cialis could be bought in once-a-day doses, which give Lilly clear lead over the other manufacturers of Viagra and Levitra.
This product will be targeted for the men who would like to have sex two or more times a week without confining it to a limited time.
Another advantage of Cialis over the Viagra and Levitra is that its dose works for about 36 hours instead of about 4 hours like competitors products.
Cialis trails rival Viagra in the U.S., however Eli Lilly and Co. is the leader in 22 nations over the world from France to Mexico, in the $3 billion market for erectile dysfunction drugs.
All medicines work by the same way, it blocks an enzyme in man, which allows him to achieve and sustain an erection.
Doctors predict that once-a-day Cialis version will catch on, Dr. Ronald Suh, from Urology of Indiana said”The baby boomer population is growing. I think a certain patient group could benefit. They want to take it now and be ready whenever.”
There are analysts who think that once-a-day version of Cialis could increase Lilly sales, but only modestly. However it could give a constant and more stable income than current dosage of Cialis, which is taken by the men sporadically.
Jason Fox, a drug analyst at H&R Block in Detroit said: “Giving consumers more options is a positive step, but I don’t think it’s going to be a game-changing development for Lilly or the erectile-dysfunction market, at least in the short run,”
“It seems more like a life-cycle management thing than something that’s completely new” noticed analyst at Miller Tabak & Co. in New York, Les Funtleyder.
The erectile-dysfunction market is continuing its way to establish and grow up from the baby boomer to the medicine cabinet for help in the bedroom.
Eli Lilly and Co. said that Cialis has continued to raise its market share every quarter since 2003 when it was launched. It is sure that any improvement in its products will show improvement also in gaining yield. Lilly also bought exclusivity of the drug from partner Icos Corp. for $2.3 billion.
The company expects that sales of the Cialis will reach $ 1 billion this year, what will give it a blockbuster status.
Lilly also added that Cialis would become No. 1 outside the U.S. in December of this year, what beat out the competitors.
However, the company didn’t make any such predictions in the U.S., where Viagra is still the leader of erectile dysfunction market. Despite that, Cialis’ market share in the U.S. rose from 14 percent in 2003 to 27 percent last year, and in the meantime Viagra’s shares fell from 73 percent to 56 percent, according to IMS Health.